Citigroup Maintains Buy on Candel Therapeutics, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 86.2%

Neg 0% Neu 0% Pos 86.2%

Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and raises the price target from $22 to $26.